MBDB
 | This article needs additional citations for verification. (November 2013) |
 | |
 Chemical structure | |
| Clinical data | |
|---|---|
| Other names | Methylbenzodioxolylbutanamine; N-Methyl-1,3-benzodioxolylbutanamine; MBDB; 3,4-Methylenedioxy-N-methyl-butanphenamine; MDMB |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| Melting point | 156 °C (313 °F) |
| |
| |
| (verify) | |
1,3-Benzodioxolyl-N-methylbutanamine (N-methyl-1,3-benzodioxolylbutanamine, MBDB, 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine) is an
MBDB was first synthesized by
MBDB was initially developed as a non-psychedelic entactogen. It has lower effects on the dopamine system in comparison to other entactogens such as MDMA.[citation needed] MBDB causes many mild, MDMA-like effects, in particular the lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, mood lift, and mild euphoria, all of which are present.[citation needed] MBDB tends to produce less euphoria, psychedelia, and stimulation in comparison to MDMA.[citation needed]
Legal Status
Unlike MDMA, MBDB is not internationally scheduled under the United Nations Convention on Psychotropic Substances. The thirty-second meeting of the WHO Expert Committee on Drug Dependence (September 2000) evaluated MBDB and recommended against scheduling.[3] From the WHO Expert Committee assessment of MBDB:
- Although MBDB is both structurally and pharmacologically similar to MDMA, the limited available data indicate that its stimulant and euphoriant effects are less pronounced than those of MDMA. There have been no reports of adverse or toxic effects of MBDB in humans. Law enforcement data on illicit trafficking of MBDB in Europe suggest that its availability and abuse may now be declining after reaching a peak during the latter half of the 1990s. For these reasons, the Committee did not consider the abuse liability of MBDB would constitute a significant risk to public health, thereby warranting its placement under international control. Scheduling of MBDB was therefore not recommended.
Australia
MBDB is considered a Schedule 9 Prohibited substance in Australia under the Poisons Standard (October 2015).[4] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[4]
Russia
MBDB is included into Schedule 1 of the Controlled Substances Act. [1]
Sweden
Sveriges riksdags health ministry Statens folkhälsoinstitut classified MBDB as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Feb 25, 1999, in their regulation SFS 1999:58 listed as "2-metylamino-1-(3,4-metylendioxifenyl)-butan (MBDB)", making it illegal to sell or possess.[5]
See also
- Ethylbenzodioxolylbutanamine(EBDB; Ethyl-J)
- Methylbenzodioxolylpentanamine(MBDP; Methyl-K)
- UWA-101
References
- ^ "MBDB". Erowid Center.
- PMID 26112925.
- ^ WHO Expert Committee on Drug Dependence (2001). "Thirty-second Report, Technical Report Series 903" (PDF).
- ^ a b "Poisons Standard". Federal Register of Legislation. Australian Government. October 2015.
- ^ "Svensk författningssamling" [Swedish Code of Statutes] (PDF) (in Swedish). Notisum AB. Archived from the original (PDF) on 2018-03-06. Retrieved 2013-09-25.